Lyra Therapeutics Inc., a late-stage biotechnology company, has released a corporate presentation detailing its development of long-acting, bioabsorbable, anti-inflammatory sinonasal drug implants for treating chronic rhinosinusitis $(CRS)$. The company is currently advancing its lead program, LYR-210, aimed at approval for both non-polyp and polyp patients. The ENLIGHTEN 2 Phase 3 trial has successfully met its primary and key secondary endpoints, with pooled data showing consistent improvement over sham control in various endpoints. With a significant market opportunity in the U.S., where CRS affects approximately 12% of the population, Lyra's innovative treatment targets both CRS with and without nasal polyps. You can access the full presentation through the link below.